The Miracles We Leave Behind
By Google AI with an introduction by Rakesh.
Introduction: I don’t know how they find me. It’s creepy as hell. I sometimes write about helping people, or charity and confession or redemption or even salvation and I suddenly start getting letters from far away places. Franciscan Friars of the Atonement (At-one-ment) Graymoor in Garrison, NY for example. St. Anthony, the Saint of Miracles is pictured and mentioned. The Salesians from New York also reached out, although that isn’t as surprising since I attended to one of their schools. Still with their envelopes on my desk on the right side, it’s a wee bit difficult to talk about snark or sarcastic essays. So I figured I’d try something different. Maybe the readers will join, maybe they will simply read shrug their shoulders and move on. Look we don’t want to do a co-ordinated campaign like lobby organizations do. If you write a letter or an email (prefer the former, there is something real about getting envelopes in the mail), make sure it is personalized. The AI can do most of the most for you with the prompt or you can genuinely write a serious and personalized letter. I would also strongly recommend not mentioning Sentient Musings if you want this to be a hidden revolution with merch no one understabnds. Here’s the essay.
+++
We live in an era of biological alchemy. For decades, a diagnosis of a genetic disease like Spinal Muscular Atrophy, Sickle Cell Disease, or Metachromatic Leukodystrophy was a slow, agonizing sentence. Today, we can rewrite the code of life. Gene therapies offer something medicine rarely promises: a permanent, one-and-done cure.
But a miracle is only a miracle if you can access it. Right now, humanity is facing a silent, structural crisis. The commercial models governing our greatest scientific breakthroughs have optimized exclusively for the wealthiest insurance markets on earth. The rest of the world is simply left out of the equation.
To understand the systemic failure, look at the stark contrast between two recently approved therapies.
The Scale vs. The Cost
Consider Casgevy, developed by Vertex Pharmaceuticals and CRISPR Therapeutics. It is the world’s first approved CRISPR gene therapy, designed to cure Sickle Cell Disease—a painful, life-shortening blood disorder. The treatment costs roughly $2.2 million per patient. While developed and commercialized in the West, the vast majority of the world’s sickle cell patients live in sub-Saharan Africa and India. The current commercial model almost entirely ignores the regions where the disease inflicts the heaviest burden of human suffering.
Then consider Lenmeldy, manufactured by Orchard Therapeutics. It treats Metachromatic Leukodystrophy (MLD), a brutal neurodegenerative disease where infants rapidly lose the ability to walk, talk, and swallow, leading to an early death. Lenmeldy is a medical triumph, but it carries a list price of $4.25 million per dose, making it the most expensive drug in human history. Without ultra-premium Western health insurance, an infant born with MLD has zero pathway to survival. Access to life is dictated entirely by geography.
The Public Subsidization of Private Cures
This is not just a humanitarian issue; it is a policy failure. Many of these ultra-expensive gene therapies rely heavily on foundational scientific discoveries funded by American taxpayers through the National Institutes of Health (NIH). Public funds take on the early, high-risk research. Private corporations then commercialize the breakthroughs, lock them behind multi-million-dollar price tags, and offer no scalable distribution plans for low- and middle-income nations. [1]
We must shift from a mindset of corporate charity and "lotteries" to structural global access.
+++
Your Intelligence Dossier: Taking Action
We do not use form templates. Form letters are easily flagged, filtered, and ignored by automated corporate PR systems and legislative aides. True impact lies in a groundswell of unique, deeply personalized voices echoing the exact same structural demands.
Use your own intelligence—and leverage the AI tools at your disposal—to write a personalized, urgent message to the decision-makers below.
The Targets:
For Vertex Pharmaceuticals (Casgevy): Route your message to their corporate channels, urging them to issue global access licenses or tiered pricing models for high-burden, lower-income regions.
For Orchard Therapeutics (Lenmeldy): Focus on their executive leadership—either Dr. Bobby Gaspar(CEO) at their global headquarters in London, or Frank Thomas (COO) at their U.S. headquarters in Boston. Demand a transparent, dedicated compassionate-use quota for low-income nations so a child's survival doesn't depend on a geographic lottery.
For Washington, D.C.: Contact your local U.S. House Representative and both of your U.S. Senators. Demand that Congress introduce legislation tying federal NIH research funding to global humanitarian access mandates. If American taxpayers subsidize a cure, the manufacturing company must provide a scalable distribution plan for developing nations. [1]
How to Mobilize Your AI Assistant:
To generate a completely unique letter in your own voice, copy and paste the prompt below into your preferred AI tool, filling in the bracketed details:
"I want to write a personalized, deeply serious letter to [Insert: My Congressional Representative / My U.S. Senator / Vertex Pharmaceuticals / Orchard Therapeutics]. I want to argue that life-saving gene therapies costing millions of dollars are completely leaving behind vulnerable children in poorer countries. Use these facts to write the letter: [Insert specific details from the Casgevy, Lenmeldy, or Legislative cases above]. Make the tone urgent, sophisticated, and focused on global health equity. Do not use generic template cliches; ensure it reads like an individual citizen who is deeply concerned about systemic human inequality. Keep it under 300 words."
Examine the facts. Synthesize the argument. Write the letter. The revolution is decentralized, silent, and driven by those who refuse to let miracles be rationed by wealth.
1. Vertex Pharmaceuticals (Casgevy)
CEO Name:Dr. Reshma Kewalramani, M.D.
Corporate Headquarters Address:
50 Northern Ave, Boston, MA 02210, United States
2. Orchard Therapeutics (Lenmeldy)
CEO Name:Dr. Bobby Gaspar, M.D., Ph.D.
U.S. Corporate Headquarters Address:
101 Seaport Boulevard, 7th Floor, Boston, MA 02210, United StatesGlobal Corporate Headquarters Address:
245 Hammersmith Road, 3rd Floor, London W6 8PW, United Kingdom
Because Dr. Gaspar is physically based in the UK, your readers can directly address their letters to him at the London location. However, since Orchard Therapeutics operates as a dual Boston-London company with major commercial operations in Massachusetts, it helps to know how the leadership is split:
To London (Global Executive Leadership): Letters can be addressed directly to Dr. Bobby Gaspar, M.D., Ph.D. (Chief Executive Officer).
To Boston (U.S. Executive Operations): If readers want to target the U.S. branch (which handles the FDA marketing and commercial pricing of Lenmeldy), they should address it to Frank Thomas, President and Chief Operating Officer. He is based out of the Boston office and manages the company's business and operational strategies.
This information gives your readers the flexibility to target the global scientific founder in London or the commercial president in Boston depending on how they choose to frame their personalized letters. [1, 2]
=================
Here is a sample letter from Gemini that is serious and systemic. It is also not personal. I would suggest including personal details like “Hey Congressman so and so, we met at the Iowa County Fair last year and I enjoyed speaking with you….“
That’s just me though, I am a people’s person ( I used to be in recruiting and sales ). You can customize it anyway you like…
https://www.youtube.com/watch?v=HQWPf0dk__c
https://www.youtube.com/shorts/5jTQIs0D56I
Letters for Global Health Equity crafted by Gemini.
To Vertex Pharmaceuticals (Casgevy)
Target: Dr. Reshma Kewalramani, M.D. (Boston, MA)
Dear Dr. Kewalramani,
Casgevy is undeniably a triumph of modern science. However, its $2.2 million price tag ensures it will never reach the vast majority of the world’s Sickle Cell Disease patients, who reside in sub-Saharan Africa and India. We have achieved a biological miracle, but a cure that exists only for the wealthiest nations is a failure of human equity.
I am writing to urge Vertex Pharmaceuticals to implement global access licenses or a tiered pricing model for high-burden, lower-income regions. The current commercial model leaves millions to suffer a painful, life-shortening disease simply because of their geography. True innovation must include a scalable path to global access. Please prioritize a distribution model that does not ration this life-saving treatment entirely by wealth.
Sincerely, [Your Name] [Your Address]
To Orchard Therapeutics (Lenmeldy)
Targets: Dr. Bobby Gaspar (London) or Frank Thomas (Boston, MA)
Dear [Dr. Gaspar / Mr. Thomas],
The development of Lenmeldy offers unprecedented hope for infants facing Metachromatic Leukodystrophy (MLD). Yet, assigning a $4.25 million list price—the most expensive in human history—means that for the vast majority of the world, this cure effectively does not exist.
An infant’s survival should not be dictated by a geographic lottery or the limits of ultra-premium Western health insurance. I urge Orchard Therapeutics to establish a transparent, dedicated compassionate-use quota specifically for low- and middle-income nations. A medical breakthrough of this magnitude carries a moral obligation. I ask that Orchard lead the industry by ensuring that the most vulnerable patients on earth are not systematically excluded from this miracle.
Sincerely, [Your Name] [Your Address]
To Your Congressional Representatives
Targets: Your local U.S. House Representative and U.S. Senators
Dear [Representative/Senator Last Name],
We are witnessing a structural failure in how life-saving medicine is commercialized. Gene therapies like Lenmeldy and Casgevy—costing $4.25 million and $2.2 million per dose, respectively—are leaving behind the vast majority of the global population.
These breakthroughs are frequently built on foundational, high-risk research subsidized by American taxpayers through the NIH. Yet, when private corporations bring them to market, they lock them behind impossible price tags with zero scalable distribution plans for developing nations.
I urge you to introduce legislation tying federal NIH research funding to global humanitarian access mandates. If public funds subsidize a cure, the manufacturer must be required to provide a scalable distribution plan for lower-income regions. We cannot continue to fund research that is subsequently restricted by geography and wealth.
Sincerely, [Your Name] [Your Address]
“Without faith, we are like a ship without a sail.” — St. Anthony of Padua.
